Padget, Michelle

Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study

Lampert, E. J., Zimmer, A., Padget, M., Cimino-Mathews, A., Nair, J. R., Liu, Y., Swisher, E. M., Hodge, J. W., Nixon, A. B., Nichols, E., et al. (2020) · Clinical Cancer Research

PARP inhibition in cancer therapyOvarian cancer diagnosis and treatment

Cited by 220

Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition

Fenerty, K. E., Padget, M., Wolfson, B., Gameiro, S. R., Su, Z., Lee, J. H., Rabizadeh, S., Soon-Shiong, P., & Hodge, J. W. (2018) · Journal for ImmunoTherapy of Cancer

Immune Cell Function and InteractionPARP inhibition in cancer therapy

Cited by 68